AI Article Synopsis
- The study aimed to evaluate how well certain serum biochemical markers can diagnose advanced liver fibrosis in children with chronic hepatitis B using ROC analysis.
- Researchers tested serum levels of apolipoprotein A-I (APO A-I), haptoglobin (HPT), and a-2 macroglobulin (A2M) in 63 children with verified cases of hepatitis B.
- Although most markers didn’t effectively predict liver issues, APO A-I showed promise, with an 85.7% sensitivity for identifying advanced fibrosis.*
Article Abstract
Aim: To investigate the diagnostic accuracy of potent serum biochemical fibrosis markers in children with chronic hepatitis B evaluated by receiver operating characteristics (ROC) analysis.
Methods: We determined the serum level of apolipoprotein A-I (APO A-I), haptoglobin (HPT) and a-2 macroglobulin (A2M) with an automatic nephelometer in 63 children (age range 4-17 years, mean 10 years) with biopsy-verified chronic HBeAg-positive hepatitis B. Fibrosis stage and inflammation grade were assessed in a blinded fashion according to Batts and Ludwig. We defined mild liver fibrosis as a score < or =2 and advanced fibrosis as a score equal to 3. ROC analysis was used to calculate the power of the assays to detect advanced liver fibrosis (AccuROC, Canada).
Results: Serum concentrations of APO A-I, HPT and A2M were not significantly different in patients with chronic hepatitis B compared to controls. However, APO A-I level of 1.19 ng/L had a sensitivity of 85.7% and a specificity of 60.7% (AUC = 0.7117, P = 0.035) to predict advanced fibrosis. All other serum biochemical markers and their combination did not allow a useful prediction. None of these markers was a good predictor of histologic inflammation.
Conclusion: Apolipoprotein A-I may be a suitable serum marker to predict advanced liver fibrosis in children with chronic hepatitis B.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4725072 | PMC |
| http://dx.doi.org/10.3748/wjg.v11.i45.7192 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Disease Progression Mathematical Modeling With a Case Study on Hepatitis B Virus Infection.
CPT Pharmacometrics Syst Pharmacol
December 2024
Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida, Orlando, Florida, USA.
Chronic Hepatitis B presents a significant health and socioeconomic burden. The risk of hepatocellular carcinoma remains elevated although treatments are available. Achieving an optimal treatment regimen necessitates a deep comprehension of the dynamic relationship between the virus and its host across disease states.
View Article and Find Full Text PDFUrinary Circular RNA Panels to Detect HBV-Related Hepatocellular Carcinoma: A Multicenter, Large-Scale, Case-Control Study.
J Natl Compr Canc Netw
December 2024
1Department of Hepatology, The Fifth People's Hospital of Ganzhou, Ganzhou, Jiangxi Province, China.
Purpose: More than 60% of patients with hepatocellular carcinoma (HCC) do not receive curative therapeutics due to late clinical manifestations and diagnosis. The 5-year survival rate for advanced HCC is approximately 2%. However, curative therapies for HCC detected early can improve the 5-year survival rate to >70%.
View Article and Find Full Text PDFMolecular mechanisms behind the inhibitory effects of ginsenoside Rg3 on hepatic fibrosis: a review.
Arch Toxicol
December 2024
College of Chinese Medicinal Materials, Jilin Provincial International Joint Research Center for the Development and Utilization of Authentic Medicinal Materials, Jilin Agricultural University, Changchun, 130118, China.
Hepatitis is a chronic inflammatory liver disease and an important cause of liver fibrosis, which can progress to cirrhosis and even hepatocellular carcinoma if left untreated. However, liver fibrosis is a reversible disease, so finding new intervention targets and molecular markers is the key to preventing and treating liver fibrosis. Ginseng, the roots of Panax ginseng C.
View Article and Find Full Text PDFClinical Features and Transition of Acute Hepatitis B Virus Infection.
J Viral Hepat
February 2025
Department of Hepatology, Nanjing Second Hospital, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Acute hepatitis B (AHB) is generally a self-limiting illness in adults and most patients achieve hepatitis B surface antigen (HBsAg) clearance within 6 months. We aimed to investigate the proportion and influencing factors of chronic outcome in adult AHB patients. A total of 126 consecutive AHB patients were included between January 2013 and October 2018.
View Article and Find Full Text PDFFrom Paper to Digital: Performance and Challenges of the Electronic Hepatitis B Surveillance System in Ninh Binh, Northern Vietnam (2017-2022).
Trop Med Infect Dis
December 2024
National Centre for Epidemiology and Population Health, College of Health and Medicine, Australian National University, Canberra, ACT 2601, Australia.
Hepatitis B remains a major public health issue in Vietnam. Mandatory reporting to the national electronic communicable disease surveillance system (eCDS) has been required since July 2016. We conducted an evaluation of the hepatitis B surveillance system in Ninh Binh, the province with the highest reported burden of hepatitis B in Northern Vietnam, between 2017 and 2022.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!